
    
      - This is a multi-center, AZD9291 expanded access protocol for the treatment of adult
      patients with advanced/metastatic EGFR T790M mutation-positive non-small cell lung cancer
      (NSCLC) who have received prior EGFR TKI therapy and at least one additional line of therapy
      (â‰¥ 3rd line). Local testing is accepted for confirmation of T790 mutation status. Eligible
      patients will be enrolled to receive AZD9291 (80mg orally, once daily) for as long as the
      access program remains open and they are continuing to show clinical benefit, as judged by
      the treating physician
    
  